Dr. Ashok Amin Joins Advaxis as Vice President of Research and Development

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has appointed Dr. Ashok Amin as Vice President of Research and Development.

Dr. Amin has held an impressive range of academic positions, including Director of Rheumatology Research at the Hospital for Joint Diseases at New York University, Director of Translational Research at the Virginia College of Medicine (VCOM), Professor and Chairman of the Department of Genetics at VCOM and Vice President of Research at the Carilion Clinic in Roanoke, Virginia. He has acted as a collaborator or consultant to 17 different pharmaceutical companies, including Schering Plough (NYSE: MRK), Dupont-Merck, Yamanouchi Pharmaceuticals, Ranbaxy Laboratories, Ltd (OTC: RBXLY), and Forest Laboratories (NYSE: FRX).

He has served on over 20 editorial boards or as an ad hoc reviewer for many leading scientific publications including Journal of Immunology, Nature, The New England Journal of Medicine, Science and The Wall Street Journal. He has acted as investigator or administrator on over 40 clinical trials, filed 15 patents, and authored 80 peer-reviewed journal articles, reviews and book chapters. He has been an invited speaker or chairperson at numerous international scientific meetings. While Director of Research at NYU’s Hospital for Joint Diseases, Dr. Amin’s team discovered the drug ORACEA® (doxycycline, USP), which is currently being marketed by Galderma for the treatment of rosacea.

“Dr. Amin will be a valuable addition to our scientific team,” commented Advaxis Chairman / CEO Thomas A. Moore. “As an expert in translational research, he will lead our R&D team in the discovery, lead optimization and pre-clinical development of our future immunotherapies. He will also broaden our research capabilities beyond oncology. Dr. Amin will be an effective spokesperson for Advaxis in scientific circles around the world based on his experience in drug development “from bench to bedside and back.”

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis Incorporated
Conrad Mir, Executive Director
609-452-9813 (Office)
609-452-9818 (FAX)
[email protected]
or
Advaxis Incorporated
Diana Moore, Analyst
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.